CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population

DNA and Cell Biology

Volumn 25, Issue 5, 2006, Pages 287-294

  Sobti, R C ^a   Onsory, Khadijeh ^a   Al Badran, Adnan Issa ^a   Kaur, Pushpinder ^a   Watanabe, Masatoshi ^b   Krishan, A ^c   Mohan, Harsh ^d  

^a PANJAB UNIVERSITY   (India)

^b YOKOHAMA NATIONAL UNIVERSITY   (Japan)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 17; CYTOCHROME P450 1B1; CYTOCHROME P450 2D6; GENOMIC DNA; ISOENZYME; STEROID 5ALPHA REDUCTASE;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POINT MUTATION; POLYMERASE CHAIN REACTION; POPULATION GENETICS; POPULATION RISK; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BASE SEQUENCE; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INDIA; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 33744824667     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2006.25.287     Document Type: Article

References (44)

1. AGUNDEZ, J.A.G., MARTINEZ. C., OLIVERA, M., GALLARDO, L., LADERO, J.M., ROSADO, C., PRADOS, J., RODRIGUES-MOLINA, J., RESEL, L., and BENITEZ, J. (1998). Expression in human prostate of drug- and carcinogen-metabolizing enzymes: Association with prostate cancer risk. Br. J. Cancer 78, 1361-1367.
2. AKHTAR, M.K., KELLY, S.L., and KADERBHAI, M.A. (2005). Cytochrome b(5) modulation of 17{alpha} hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis. J Endocrinol. 187, 267-274.
3. ALLEN, N.E., FORREST, M.S., and KEY, T.J. (2001). The association between polymorphisms in the CYP17 and 5a-reductase (SRD5A2) genes and serum androgen concentrations in Men1. Cancer Epidemiol. Biomarkers Prevent. 10, 185-189.
4. BRESLOW, N.E., and DAY, N.E. (1980). Statistical Methods in Cancer Research: Analysis of Case-Control Studies (Lyon, France: IARC).
5. CAREY, A.H., WATERWORTH, D., PATEL, K., WHITE, D., LITTLE, J., NOVELLI, P., FRANKS, S., and WILLIAMSON, R. (1994). Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum. Mol. Genet. 3, 1873-1876.
6. CICEK, M.S., CONTI, D.V., CURRAN, A., NEVILLE, P.J., PARIS, P.L., CASEY, G., and WITTE, J.S. (2004). Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and AR. Prostate 59, 69-76.
7. DOS SANTOS, A., RIBEIRO, M.L., MESQUITA, J.C., CARVALHO-SALLES, A.B., and HACKEL, C. (2002). No association of the 5′ promoter region polymorphism of CYP17 gene with prostate cancer risk. Prostate Cancer Prostatic Dis. 5, 28-31.
8. FEBBO, G.F., KANTOFF, P.W., GIOVANNUCCI, E., BROWN, M., CHANG, G., HENNEKENS, C.H., and STAMPFER, M. (1998). Debrisoquine hydroxylase (CYP2D6) and prostate cancer. Cancer Epidemiol. Biol. Prevent. 7, 1075-1078.
9. FEBBO, P.G., KANTOFF, P.W., PLATZ, E.A., CASEY, D., BATTER, S., GIOVANNUCHI, E., HENNEKENS, C.H., and STAMPFER, M.J. (1999). The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Res. 59, 5878-5881.
10. FEIGELSON, H.S., SHAMES, L.S., PIKE, M.C., COETZEE, G.A., STANCZYK, F.Z., and HENDERSON, B.E. (1998). A cytochrome p450c17a gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res. 58, 585-587.
11. FUKATSU, T., HIROKAW, Y., ARAKI, T., HIOKI, T., MURATA, T., SUZUKI, H., ICHIKAWA, T., TSUKINO, H., QIU, D., KATOH, T., et al. (2004). Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res. 24, 2431-2437.
12. GSUR, A., BERNHOFER, G., HINTEREGGER, S., HAIDINGER, G., SCHATZL, G., MADERSBACHER, S., MARBERGER, M., VUTUC, C., and MICKSCHE, M. (2000). A polymorphism in the CYPl7 gene is associated with prostate cancer risk. Int. J. Cancer 87, 434-437.
13. HABIB, F.K., ROSS, M., BAYNE, C.W., BOLLINA, P., GRIGOR, K., and CHAPMAN, K. (2003). The loss of 5-alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis. Clin. Cancer Res. 9, 1815-1819.
14. HABUCHI, T., LIQING, Z., SUZUKI, T., SASAKI, R., TSUCHIYA, N., TACHIKI, H., SHIMODA, N., SATOH, S., SATO, K., KAKEHI, Y., et al. (2000). Increased risk of prostate cancer and begin prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res. 60, 5710-5713.
15. HAIMAN, C.A., STAMPFER, M.J., GIOVANNUCCI, E., MA, J., DECALO, N.B., KANTOFF, P.W., and HUNTER, D.J. (2001). The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol. Biomarkers Prevent. 10, 743-748.
16. HSING, A.W., CHEN, C., CHOKKALINGAM, A.P., GAO, Y.T., DIGHTMAN, D.A., NGUYEN, H.T., DENG, J., CHENG, J., SESTERHENN, I.A., MOSTOFI, F.K., et al. (2001). Polymorphic markers in the SRD5A2 gene and prostate cancer risk: A population-based case-control study. Cancer Epidemiol. Biomarkcrs Prevent. 10, 1077-1082.
17. KITTLES, R.A., PANGULURI, R.K., CHEN, W., MASSAC, A., AHAGHOTU, C., JACKSON, A., UKOLI, F., ADAMS-CAMPBELL, L., ISAACS, W., and DUNSTON, G.M. (2001). CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol. Biomarkers Prevent. 10, 943-947.
18. LADERO, J., BENITEZ, J., JARA, C., LLERENA, A., VALDIVIELSO, M., MUNOZ, J., and VARGAS, E. (1991). Polymorphic oxidation of debrisoquine in women with breast cancer. Oncology 48, 107-110.
19. LAMHARZI, N., JOHNSON, M.M., GOODMAN, G., ETZIONI, R., WEISS, N.S., DIGHTMAN, D.A., BARNETT, M., DITOMMASO, D., and CHEN, C. (2003). Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer. Int. J. Cancer 105, 480-483.
20. LATIL, A.G., AZZOUZI, R., CANCEL, G.S., GUILLAUME, E.C., COCHAN-PRIOLLETE, B., BERTHON, P.L., and CUSSENOT, O. (2001). Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 92, 1130-1137.
21. LI, Z., HABUCHI, T., MITSUMORI, K., KAMOTO, T., KINOSHITU, H., SEGAWA, T., OGAWA, O., and KATO, T. (2003). Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J. Urol. 169, 2378-2381.
22. LIU, J.H., LI, H.W., TONG, M., LI, M., and NA, Y.Q. (2004). Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer. Zhonghua Yi Xue Za Zhi 84, 364-368.
23. LUNN, R.M., BELL, D.A., MOHLER, J.L., and TAYLOR, J.A. (1999). Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis (Lond.) 20, 1727-1731.
24. MAKRIDAKIS, N., ROSS, R.K., PIKE, M.C., CHANG, L., STANCZYK, F.Z., KOLONEL, L.N., SHI, C.-Y., YU, M.C., HENDERSON, B.E., and REICHARDT, J.K.V. (1997). A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res. 57, 1020-1022.
25. MAKRIDAKIS, N.M., DI SALLE, E., and REICHARDT, J.K. (2000). Biochemical and pharmacogenctic dissection of human steroid 5α-reductase type II. Pharmacogenctics 10, 407-413.
26. MURRAY, G., TAYLOR, M., MCFADYEN, M., MCKAY, J., GREENLEE, W., BURKE, M., and MELVIN, W. (1997). Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57, 3026-3031.
27. NAM, R.K., ZHANG, W.W., TRACHTENBERG, J., JEWETT, M.A., EMAMI, M., VESPRINI, D., CHU, W., HO, M., SWEET, J., EVANS, A., et al. (2003). Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol. Biomarkers Prevent. 12, 1429-1437.
28. NTAIS, C., POLYCARPOU, A., and IOANNIDIS, J.P. (2003a). Association of the CYP17 gene polymorphism with the risk of prostate cancer: A meta-analysis. Cancer Epidemiol. Biomarkers Prevent. 12, 120-126.
29. NTAIS, C., POLYCARPOU, A., and IOANNIDIS, J.P. (2003b). SRD5A2 gene polymorphisms and the risk of prostate cancer: A meta-analysis. Cancer Epidemiol. Biomarkers Prevent. 12, 618-624.
30. PICARDO-LEONARD, J., and MILLER, W.L. (1987). Cloning and sequence of the human gene for p450c 17 (steroid 17a-hydroxylase/17. 20 lyase): Similarity with the gene for P450c2I. DNA 6, 439-448.
31. SALAM, M.T., URSIN, G., SKINNER, E.C., DESSISSA, T., and REICHARDT, J.K. (2005). Association between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol. Oncol. 23, 246-253.
32. SAMBROOK, J., FRITSH, E.F., and MANIATIS, T. (1989). Molecular Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).
33. SHIMADA, T., HAYES, C.L., YAMAZAKI, H., AMIN, A., HECHT, S., GUENGERICH, P.P., and SUTTER, T.R., (1996). Activation of chemically diverse procarcinogens by human cytochrome P-450 IBI. Cancer Res. 56, 2979-2984.
34. SMITH, C.A., MOSS, J.E., GOUGH, A.C., SPURR, N.K., and WOLF, C.R. (1992). Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ. Health Perspect. 98, 107-112.
35. SUTTER, T.R., TANG, Y.M., HAYES, C.L., WO, Y.P., JABS, E.W., LI, X., YIN, H., CODY, C.W., and GREENLEE, W.F. (1994). Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol Chem. 269, 13092-13099.
36. TANG, Y.M., WO, Y.Y., STEWART, J., HAWKINS, A.L., GRIFFINS, C.A., SUTTER, T.R., and GREENLEE, W.F. (1996). Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J. Biol. Chem. 271, 28324-28330.
37. TANG, Y.M., GREEN, B.L., CHEN, G.F., THOMPSON, P.A., LANG, N.P., SHINDE, A., LIN, D.X., TAN, W., LYN-COOK, B.D., HAMMONS, G.J., et al. (2000). Human CYP1B1 Leu432Val gene polymorphism: Ethnic distribution in African-American, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 10, 761-766.
38. TIGLI, H., YAZICI, H., and DALAY, N. (2003). Cyp17 genetic polymorphism in prostate cancer and benign prostate hyperplasia. Res. Commun. Mol. Pathol. Pharmacol. 113-114, 307-314.
39. VILCHIS, F., HERNANDEZ, D., CANTO, P., MENDEZ J.P., and CHAVEZ, B. (1997). Codon 89 polymorphism of the human 5 alpha-steroid reductase type 2 gene. Clin Genet. 51, 399-402.
40. WADELIUS, M., ANDERSON, S.-O., JOHANSSON, J.-E., WADELIUS, C., and RANE, A. (1999). Prostate cancer associated with CYP17 genotype. Pharmacogenetics 9, 635-639.
41. WATANABE, M., HIROKAWA, Y., and SHIRAISHI, T. (2005). Polymorphisms of hormone related genes and prostate cancer risk in Japan. Nippon Rnshio 63, 219-224.
42. WILDING, G. (1995). Endocrine control of prostate cancer. Cancer Surv. 23, 43-62.
43. YAMADA, Y., WATANABE, M., MURATA, M., YAMANAKA, M., KUBOTA, Y., ITO, H., KATOH, T., KAWAMURA, J., YATANI, R., and SHIRAISHI, T. (2001). Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5α-reductase type II (SRD5A2) genes on prostate-cancer risk among risk among the Japanese population. Int. J. Cancer 92, 683-686.
44. ZHU, B.T., and CONNEY, A.H. (1998). Functional role of estrogen metabolism in target cells: Review and perspectives. Carcinogenesis (Lond.) 19, 1-27.